B3

(54) Title: METHOD OF INDUCING TUMOR CELL APOPTOSIS USING TRAIL/APO-2 LIGAND GENE TRANSFER

(57) Abstract: The present invention is directed to methods for inhibiting tumor cell growth, causing tumor regression or eliminating tumor cells in a mammal afflicted with a tumor by administering to a TRAIL-sensitive cell a vector having a DNA expression cassette containing a promoter and a DNA sequence encoding TRAIL, wherein the expression of TRAIL results in tumor inhibition, regression or elimination.

WO 01/79495 A1

—   *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHOD OF INDUCING TUMOR CELL APOPTOSIS USING
TRAIL/APO-2 LIGAND GENE TRANSFER

5

Background of the Invention

Members of the tumor necrosis factor (TNF) superfamily of cytokines influence a variety of immunological functions, including cellular activation,

10 proliferation, and death, upon interaction with a corresponding superfamily of receptors (1-3). Interest in the apoptosis-inducing molecules TNF and Fas ligand has been peaked due to their participation in events such as autoimmune disorders, activation-induced cell death, immune privilege, and tumor evasion from the immune system (4-8). Another death-inducing family member, TRAIL

15 (TNF-related apoptosis-inducing ligand, also referred to as Apo-2 ligand or Apo-2L) is generating excitement because of its apparent unique ability to induce apoptosis in a wide range of transformed cell lines but not in normal tissues and cells (9,10).

To date, four homologous, but distinct, human TRAIL receptors have

20 been identified, with two [DR4 (11; hereafter referred to as TRAIL-R1) and DR5/TRAIL-R2 (12-15)] having the ability to initiate the apoptosis signaling cascade after ligation and two [TRID/DcR1/TRAIL-R3 (12,13,15,16) and TRAIL-R4/DcR2/TRUNDD (17-19)] lacking this ability. Because they lack the ability to directly signal cell death, TRAIL-R3 and TRAIL-R4 have been

25 hypothesized as being protective receptors, either by acting as "decoy" receptors (11,12,18,19) or via transduction of an anti-apoptotic signal (17).

Given the tumor cell-selectivity of TRAIL's cytotoxicity from results obtained *in vitro,* recent studies have examined the safety and antitumor activity of recombinant, soluble TRAIL *in vivo* (20-22). TRAIL was found to be well

30 tolerated when multiple doses were given to normal animals, and no histological or functional changes were observed in any of the tissues or organs examined. These results were dramatically different from those seen in animals given other apoptosis-inducing molecules, as injection of recombinant Fas ligand or anti-Fas monoclonal antibody (mAb) into animals rapidly induced massive hepatocyte

degeneration, necrosis, and hemorrhage, and ultimately death (20,23,24).
Moreover, multiple injections of soluble TRAIL into mice beginning the day
after tumor implantation significantly suppressed the growth of the tumors, with
many animals being tumor-free (20-22). .

5   A major drawback to these findings was that large amounts of soluble
TRAIL were required to inhibit tumor formation. This may be due to the
pharmacokinetic profile of soluble TRAIL that indicated that after intravenous
injection the majority of the protein is cleared within 5 hours (20). Increasing
the *in vivo* half-life of recombinant soluble TRAIL or developing an alternative

10 means of delivery may increase the relative tumoricidal activity of TRAIL such
that larger, more establish tumors could be eradicated as efficiently as smaller
tumors. The identification of alternate methods to deliver TRAIL to the tumor
site, however, is also critical for the further development and testing of the anti-
tumor activity of TRAIL *in vivo*.

15   The development of alternate or adjuvant forms of cancer therapy is
crucial, due to the increasing rates of many cancers throughout the world. For
example, prostate cancer is one of the most prevalent cancers among U.S. males,
with annual death rates currently estimated at over 40,000 (61). Current
treatment for localized prostate cancer is limited to surgery or radiation therapy,

20 whereas androgen ablation is generally accepted as the best method for treating
metastatic prostate cancer. Unfortunately, a significant number of patients with
advanced prostate cancer fail to demonstrate any initial positive response to
androgen ablation therapy. Moreover, prostatic cells often lose their dependency
on androgen during cancer progression, and androgen ablation becomes

25 ineffective, leading to tumor progression and death within 3 years.

   With the incidence of cancer and deaths resulting form cancer increasing,
there remains a continuing need for the development of alternative therapeutic
molecules and treatments for cancer. In particular, there is an on-going need for
therapies that have minimal toxic side effects.

30

Summary of the Invention

The present invention provides a method for inhibiting tumor cell growth in a mammal afflicted with a tumor comprising administering a vector comprising a DNA expression cassette comprising a promoter and a DNA

5   sequence encoding TRAIL, wherein the expression of TRAIL protein results in tumor inhibition. The vector may be a non-replicative viral vector. The vector may be adenovirus, adeno-associated virus, herpesvirus, lentivirus, retrovirus, vaccinia virus, or other gene delivery vector, or naked DNA. The TRAIL may be human TRAIL. The promoter used in the present invention may be, but is not

10   limited to, a cytomegalovirus promoter, an RSV promoter, or a tissue-specific promoter. The expression cassette may further comprise regulatory elements including, but not limited to, enhancers and tissue-specific regulatory elements regulating TRAIL expression or controlling viral replication. The method of the present invention may also include administering a chemotherapeutic agent, a

15   radiotherapeutic agent, or an immune potentiating gene or protein.

The tumor to be treated using the method of the present invention may be a solid tumor and may be cancerous. In particular, the solid tumor may be a lung tumor, a melanoma, a mesothelioma, a mediastinum tumor, esophagal tumor, stomach tumor, pancreal tumor, renal tumor, liver tumor, hepatobiliary system

20   tumor, small intestine tumor, colon tumor, rectum tumor, anal tumor, kidney tumor, ureter tumor, bladder tumor, prostate tumor, urethral tumor, testicular tumor, gynecological organ tumor, ovarian tumor, breast tumor, endocrine system tumor, or central nervous system tumor.

In the present invention, the vector may be administered by injection.

25   The vector may be administered in combination with a pharmaceutically acceptable carrier. The carrier may be a solution or a slurry, such as Gelfoam® or a matrix. The carrier may further contain an agent that enhances gene delivery and/or expression. The carrier may contain immune enhancing agents such as cytokines.

30   The term "mammal" as used herein refers to any mammal classified as a mammal, including humans, cows, horses, dogs and cats. In particular, the mammal is a human.

The present invention further provides a method for causing tumor regression or elimination in a mammal afflicted with a tumor comprising administering to a TRAIL-sensitive cell a vector comprising DNA encoding TRAIL, wherein the expression of TRAIL protein results in tumor regression or

5   elimination.

The term "inhibition" refers to the halting of the cellular reproduction or growth of a tumor; "regression" refers to the decrease in size of a tumor; and "elimination" refers to the eradication of most or all of the tumor cells. The terms "cancer" and "malignant" are used interchangeably in the present

10   application. "Cancer" or "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. The term "biologically active" for the purposes herein means having the ability to induce or stimulate apoptosis in at least one type of mammalian cell *in vivo* or *ex vivo*.

15   **Brief Description of the Drawings**

Figure 1. Generation of adenovirus encoding hTRAIL (Ad5-TRAIL). (A). Map of the vector used to generate Ad5-TRAIL. Map units (m.u.) 2-8, which contains the E1 genes, were deleted from the adenoviral backbone. The hTRAIL cDNA was positioned into the vector behind the immediate early CMV

20   promotor, and in front of the SV40 polyadenylation sequence. Transfection of this vector into human embryonic kidney 293 cells was performed for viral propagation. (B). Ad5-TRAIL-infected 293 cells express TRAIL protein. Cell lysates from uninfected or Ad5-TRAIL-infected 293 cells were prepared 24 hours after infection, and TRAIL protein production was determined by Western

25   blot analysis. Molecular weights listed are in kD.

Figure 2. Susceptibility of human tumor cell lines and normal prostate epithelial cells to adenovirus infection. (A). 24-well plates were seeded with 10^5 cells/well and allowed to attach for at least 6 hours before infecting with Ad5-GFP (1000 pfu/cell for 4 hours) as described in Example 2 below. Infection

30   efficiency was determined after 24 hours incubation by flow cytometry, and open histograms represent uninfected cells and filled histograms represent Ad5-GFP-infected cells. The percentage of GFP-positive cells is indicated for each cell type. All histograms represent 10^4 gated cells, and viability was >95% as

assessed by propidium iodide exclusion. (B). 96-well plates were seeded with 10^4 cells/well and allowed to attached for at least 6 hours before infection with Ad5-βgal at the indicated number of pfu/cell for 4 hours. β-galactosidase activity was determined after 24 hours incubation using a chemiluminescent

5   reporter gene assay system as described in Example 2 below. Experiments reported in (A) and (B) were repeated at least three times with similar results.

Figure 3. Death of PC-3 cells after Ad5-TRAIL infection results from increased production of TRAIL protein. (A). Microtiter plates were seeded with 2×10^4 cells/well and allowed to adhere for at least 6 hours before infection with

10 Ad5-TRAIL, Ad5-βgal, or Ad5-GFP at the indicated number of pfu/cell for 4 hours. Cells were washed with PBS, and then incubated with medium alone or medium containing recombinant TRAIL (rTRAIL) at the indicated concentrations. Cell viability was determined after 20 hours by crystal violet staining. Each value represents the mean of three wells. For clarity, S.D. bars

15 were omitted, but were <5% for all data points. Similar results were observed in three independent experiments. (B). Production of TRAIL protein following Ad5-TRAIL infection. 24-well plates containing 5×10^5 cells/well were infected with Ad5-TRAIL or Ad5-βgal (1000 pfu/cell) for 4 hours, cell lysates were prepared at the indicated times after infection, and TRAIL protein levels

20 were determined by Western blot analysis. Lysates of uninfected PC-3 cells or Ad5-TRAIL-infected 293 cells were used as negative and positive controls, respectively.

Figure 4. Ad5-TRAIL-infected PC-3 cells undergo apoptotic cell death. (A). Kinetics of caspase-8 and PARP cleavage following Ad5-TRAIL infection.

25 24-well plates containing 5×10^5 cells were infected with Ad5-TRAIL or Ad5-βgal (1000 pfu/cell) for 4 hours, cell lysates were prepared at the indicated times after infection, and caspase-8 and PARP cleavage was determined by Western blot analysis. Caspase-8 activation yields an 18 kD active subunit from the 55 kD inactive form. Cleavage of PARP from 116 kD to 85 kD occurs during

30 apoptotic cell death. For comparison, lysates from uninfected or Ad5-βgal-infected PC-3 cells were also examined. (B). Inhibition of Ad5-TRAIL-induced apoptosis by z-VAD-fmk. Microtiter plates were seeded with 2×10^4 cells/well and allowed to adhere for at least 6 hours. Ad5-TRAIL infection (1000 pfu/cell)

was done in the presence of either z-VAD-fmk (20 μM) or DMSO, which were
also added to the medium after infection. Cells infected with Ad5-TRAIL or
Ad5-βgal in medium alone served as controls. Cell viability was determined
after 20 hours by crystal violet staining. Each value represents the mean of 3
5   wells. For clarity, standard deviation bars were omitted from the graph, but were
less than 5% for all data points. Experiments were performed at least three
separate times with similar results. (C). Ad5-TRAIL-infected cells externalize
phosphatidylserine (PS). PC-3 cells were infected with Ad5-TRAIL or Ad5-
βgal (1000 pfu/cell) for 4 hours, and then cultured for 6 hours in complete
10 medium. Cells were then stained with FITC-annexin V and analyzed by flow
cytometry. Cells treated with recombinant, soluble TRAIL (100 ng/ml) served
as a positive control. The percent of FITC-annexin V positive tumor cells is
indicated for each condition. Histograms represent 10^4 gated tumor cells.

        Figure 5. TRAIL expression following Ad5-TRAIL infection. (A) Flow
15 cytometric analysis of TRAIL protein expression on WM 164 cells. WM 164
cells were infected with Ad5-βgal or Ad5-TRAIL (1000 pfu/cell) for 4 hours,
and then analyzed for TRAIL expression after 12 hours. Some of the Ad5-
TRAIL-infected cells were also cultured in the presence of Brefeldin A (BFA; 5
μg/ml) during and after infection. Open histograms represent staining by the
20 isotype control, whereas filled histograms represent staining by M181 (anti-
TRAIL mAb). Histograms represent 10^4 gated cells in all conditions. (B).
Brefeldin A treatment does not inhibit TRAIL protein production. WM 164 cells
were infected in the absence or presence of Brefeldin A (5 μg/ml) with Ad5-
TRAIL (1000 pfu/cell) for 4 hours, cell lysates were prepared at the indicated
25 times after infection, and TRAIL protein levels were determined by Western blot
analysis. A lysate of Ad5-TRAIL-infected 293 cells was used as a positive
control.

        Figure 6. Tumor cell death after Ad5-TRAIL infection can be inhibited
by Brefeldin A, but not TRAIL receptor:Fc. Microtiter plates were seeded with 2
30 X 10^4 PC-3 cells/well and allowed to adhere for at least 6 hours before infection
with Ad5-TRAIL alone or in the presence of (A) TRAIL-R2:Fc (TR-2:Fc; 20
μg/ml), (A) Fas:Fc (20 μg/ml), (B) Brefeldin A (BFA; 5 μg/ml), (B) EtOH, or
Ad5-βgal alone at the indicated number of pfu/cell for 4 hours. Cells were

washed with PBS, and then incubated with medium alone, medium containing
TR-2:Fc, Fas:Fc, BFA, or EtOH, or medium containing recombinant TRAIL
(rTRAIL) at the indicated concentrations. Cell viability was determined after 20
hours by crystal violet staining. (C). PrEC or WM 164 cells were infected with

5   Ad5-TRAIL (1000 pfu/cell) for 4 hours, incubated for 12 hours, and then
cultured for 8 hours with ^{51}Cr-labeled PC-3 target cells at the indicated effector-
target cell ratios. Soluble TRAIL or uninfected PrEC or WM 164 cells were
used as positive and negative controls, respectively, and added to target cells as
indicated. (D) Inclusion of the fusion protein TRAIL-R2:Fc (20 µg/ml) to Ad5-

10   TRAIL-infected WM 164 cells inhibited killing of PC-3 target cells, while
addition of Fas:Fc (20 µg/ml) did not. Each value represents the mean of three
wells. For clarity, S.D. bars were omitted, but were <5% for all data points.
Similar results were observed in three independent experiments.

Detailed Description of the Invention

15   Cell death by necrosis is a pathologic form of cell death resulting from
some trauma or cellular injury and is characterized by swelling of the cell,
disintegration of the cell membrane and nuclear flocculation. Cell death by
apoptosis occurs naturally in many physiological processes, including embryonic
development and clonal selection in the immune system, and usually proceeds in

20   an orderly or controlled manner. Apoptosis is characterized by cell shrinkage,
membrane vesicle formation and condensation of chromatin. Decreased levels
of apoptotic cell death have been associated with a variety of pathological
conditions including cancer, lupus, and herpes virus infection. The present
invention is based on the finding that when a vector expressing a nucleic acid

25   expression cassette encoding TRAIL was introduced into a TRAIL-sensitive
tumor cell, TRAIL protein was produced, which rapidly led to cell death by
apoptosis.

The identification of TRAIL several years ago generated a great deal of
interest, when it was determined that it appeared to have the ability to induce

30   apoptosis in a variety of tumor cell lines but not in normal cells *in vitro*.
Moreover, it was observed that TRAIL mRNA is constitutively expressed in a
wide variety of cells and tissues. These were unusual characteristics for a death-
inducing molecule in the TNF family, as the expression of TNF, LT-α, and Fas

7

ligand is tightly regulated since they can have toxic effects on normal tissues. The tumor-specific activity of TRAIL was extended *in vivo* with the observation that treatment of SCID and nude mice bearing human tumors with soluble TRAIL significantly inhibited tumor outgrowth without any observable toxic

5   side effects to the host (20-22). This inhibition of tumor outgrowth, though, required high amounts of TRAIL given over several days shortly after tumor implantation. Pharmacokinetic analysis revealed that soluble TRAIL given to mice intravenously displayed an elimination half-life of just under 5 hours(20). Given that many normal tissues express mRNA for at least one of the four

10   TRAIL receptors, this suggests that almost all the tissues in the body have the potential to bind and sequester soluble TRAIL and, thus, prevent it from reaching the tumor.

An alternative approach would be to administer TRAIL locally, where it would exist at a greater concentration and have a better chance of significantly

15   inducing tumor cell death. Such localized, intratumoral injections of soluble TRAIL would, however, be limited in that only a relatively small volume could be administered, suggesting that a potentially suboptimal amount of TRAIL protein would be used. In contrast, adenovirus (or an alternate gene delivery vehicle) can be produced at high levels, such that small volumes would contain

20   high numbers of vectors carrying the TRAIL gene. The use of the CMV promoter to drive the transcription of the transferred TRAIL gene serves as an additional mechanism to further increase the local concentration of TRAIL protein because it is not transcriptionally regulated in the same manner as the TRAIL promoter. Only when the process of apoptosis has disrupted cellular

25   functions sufficiently to affect protein production in the Ad-TRAIL-infected tumor cell will the generation of TRAIL stop. In addition to the direct elimination of tumors by the induction of apoptosis, TRAIL-induced apoptotic bodies can function to enhance tumor-specific immune activation. Immune activation may be potentiated by co-delivery of immune activation agents such

30   as cytokines or genes coding for these agents.

The concept of gene therapy has recently developed into a viable method of treating malignant transformation and cancer progression. Whereas some therapies have focused on replacing absent critical functional genes in the target

cells to restore a normal phenotype, other approaches have been based on introducing genes that encode immunostimulatory molecules to activate the immune system against the tumor. Many of these studies have employed the use of replication-deficient adenoviral vectors derived from adenovirus type 5 (Ad5)

5   to transfer the gene of interest into the target tumor cells. For example, adenoviral vectors encoding CD80, IFN-β, IL-2, IL-7, and IL-12 have all demonstrated the ability to stimulate antitumor responses after administration (41-46). The combination of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene and ganciclovir therapy has proved

10   efficacious in treating prostate cancer (47,48). Also, adenoviral vectors expressing Fas ligand have been tested in the treatment of prostate cancer models, experimental glioma, and renal carcinoma (49-51).

Even with these promising observations, immunogenicity remains a potential problem with adenoviral-based vectors. Antibodies present in the

15   patient may quickly neutralize the adenovirus before it can deliver its genetic load, as there is widespread immunity to a variety of adenovirus serotypes in humans. Recent results from a phase I clinical trial, however, reported the safety of using adenoviral vectors as a gene delivery vehicle in humans and demonstrated successful transgene expression even in the presence of pre-

20   existing immunity to adenovirus (43). Intratumoral administration of Ad5-TRAIL provides the virus with an appropriate environment for infection of the tumor and surrounding tissue, which leads to gene expression and sufficient TRAIL protein production to induce tumor cell death.

It was surprising that there were differences in tumor cell death following

25   Ad5-TRAIL infection as compared to soluble TRAIL-induced death. The relative activity of Ad5-TRAIL is dependent upon its ability to infect a target cell. Adenovirus infection requires the expression of CAR (coxsackievirus and adenovirus receptor) and the expression of certain integrins, such as $\alpha_v\beta_3$ and $\alpha_v\beta_5$ (31-33). All of the tumor cell lines and the normal prostate epithelial cells

30   were highly susceptible to adenovirus infection, suggesting that each cell type differentially regulated the translation of TRAIL mRNA into protein. Additional regulation may result in the transport of any TRAIL that is produced from the cytoplasm to the cell surface at different rates. The surface expression of TRAIL

9

is required for apoptosis induction as the inhibition of protein transport by Brefeldin A inhibited cell death, but not the production of TRAIL protein, following Ad5-TRAIL infection.

Whereas surface expression of TRAIL is essential for the observed

5   tumoricidal activity of Ad5-TRAIL, the sensitivity of the cell to TRAIL-induced apoptosis is also an important component of this phenomenon. This was best demonstrated by the fact that the melanoma cell line WM 164 and the normal prostate epithelial cells, which were resistant to soluble TRAIL-mediated apoptosis, were also resistant to effects of Ad5-TRAIL infection. The

10   identification of two TRAIL receptors that are capable of initiating the apoptotic machinery (TRAIL-R1 and -R2) and two that are not (TRAIL-R3 and -R4), led to the initial hypothesis that the expression of TRAIL-R3 and/or -R4 conferred resistance to TRAIL-induced death (11,12,18,19). However, this hypothesis was formulated by examining TRAIL receptor mRNA expression in several normal

15   tissues and tumor cell lines, and from experiments in which TRAIL-R3 or -R4 were overexpressed in transfected cells. Most of the tumor cell lines used in this study express TRAIL-R3 and/or -R4 yet were sensitive to TRAIL (soluble or Ad5-TRAIL-derived) mediated death (36,52) so it is unlikely that expression of either TRAIL-R3 or -R4 plays a role in determining their resistance to TRAIL.

20   One possible explanation for the resistance of the WM 164 cells to Ad5-TRAIL may come from a component of the cell death machinery called FLIP (FLICE inhibitory protein). FLIP is believed to inhibit the death receptor signaling machinery at its most proximal point by preventing the interaction of caspase-8 and/or FADD to the death domains of cross-linked death receptors,

25   and thus inhibit any downstream apoptotic signaling events (53). Intracellular levels of FLIP are high in the TRAIL-resistant melanoma cell line WM 164 (36), and high FLIP levels have also been shown to correlate with resistance to TRAIL-mediated apoptosis in primary versus transformed keratinocytes (54). While FLIP may have a protective function in the WM 164 tumor cell line, it is

30   likely to be one of several intracellular proteins that cooperate with other molecules (both intracellular and at the cell surface) to regulate TRAIL-induced death in tumor cell lines.

The participation of TRAIL-R3 and -R4 in regulating TRAIL sensitivity may be greater, however, in normal cells/tissues or primary tumors than in established tumor cell lines. The treatment of normal human umbilical vein or microvascular endothelial cells with phospholipase C (to strip the GPI-linked

5   TRAIL-R3 from the surface) and cycloheximide (to prevent the re-expression of any TRAIL-R3) sensitized these cells to TRAIL (13). This would suggest that TRAIL-R3 is a key regulator of the sensitivity of normal cells to TRAIL-induced death, but the addition of cycloheximide may inhibit the production of some other protein (perhaps FLIP) critical for TRAIL resistance. Furthermore, it is not

10   known how much TRAIL-R3 or -R4 is needed to inhibit the formation of a competent TRAIL-R1 or -R2 signaling complex. RT-PCR analysis of the normal prostate epithelial cells detected mRNA species for all four TRAIL receptors (TG, unpublished observation), making it possible for TRAIL-R3 and/or -R4 to enter into the TRAIL-ligated receptor complex on the prostate

15   epithelial cells, and thus making it incapable of initiating apoptosis. As with the tumor cell lines, it is difficult to determine at this time what is the exact mechanism that regulates TRAIL sensitivity and resistance in normal cells and tissues.

The observed "suicide"-like death of the Ad5-TRAIL-infected tumor

20   cells is not the only mechanism by which tumor cells may die with this kind of gene transfer therapy *in vivo*. The intralesional injection of Ad5-TRAIL would likely result in the infection of both cancerous and normal cells surrounding the injection site. While the normal prostate epithelial cells tested in the report were not killed when infected with Ad5-TRAIL, they still produced TRAIL protein

25   from the transferred gene as evidenced by the fact that they could then be used to kill PC-3 cells in a TRAIL-dependent manner (Figure 6C & D). This suggests that it would not be imperative for Ad5-TRAIL to infect the tumor cell, as infection in either the tumor itself or the surrounding normal tissue would lead to the localized production of TRAIL. In addition, the apoptotic death resulting

30   from Ad5-TRAIL infection may help initiate a T cell-mediated immune response against any remaining tumor cells. Recent reports have demonstrated that immature dendritic cells (DCs) can engulf apoptotic bodies and present antigens derived from these cell fragments in an MHC class I-restricted fashion upon

11

maturation, resulting the CTL activity (55,56). Likewise, the combination of
Ad5-TRAIL with an immunostimulatory cytokine (*i.e.* IL-12, IFN-γ) may result
in the initiation of a tumor-specific immune response against any remaining
tumor cells.

5   The present invention is directed to a gene delivery vehicle, such as a
adenoviral vector, engineered to carry a nucleic acid expression cassette
encoding TRAIL. The vector carrying the TRAIL gene is injected into the
tumor. Shortly after introduction of the vector into TRAIL-sensitive tumor cell
targets, TRAIL protein is produced and rapidly leads to the induction of

10 apoptosis in the tumor cells. This method of administering a vector engineered
to encode the nucleic acid for TRAIL is useful in the field of oncology for
treating solid mammalian tumors, such as cancers of the lung, melanoma,
mesothelioma, mediastinum, esophagus, stomach, pancreas, renal, liver,
hepatobiliary system, small intestine, colon, rectum, anus, kidney, ureter,

15 bladder, prostate, urethra, testicular, gynecological organs, ovarian, breast,
endocrine system, and central nervous system. Those with skill in the art will
recognize other possible solid tumor candidates.

          The use of a vector containing the TRAIL gene, as opposed to soluble
TRAIL protein, allows for a localized expression of TRAIL protein directly in

20 the tumor, resulting in high local TRAIL concentration. In addition, TRAIL
protein production is extended over time, therefore diminishing the problems
associated with rapid clearance of soluble TRAIL administered systemically.

          The TRAIL encoded by DNA of the present invention includes human
TRAIL (hTRAIL) as well as homologous TRAIL from other mammalian

25 species, TRAIL variants (both naturally occurring variants and those generated
by recombinant DNA technology), and TRAIL fragments, *i.e.*, only a portion of
the full-length protein, that retain a desired biological activity. The term
"biologically active" means having the ability to induce or stimulate apoptosis in
at least one type of mammalian cell *in vivo* or *ex vivo*. Examples of TRAIL

30 encoded by the DNA of the present invention include nucleotide sequences
encoding for TRAIL containing the entire extracellular domain. Fragments of
the extracellular domain that retain a desired biological activity are also
provided. Such fragments advantageously include regions of TRAIL that are

12

conserved in proteins of the TNF family of ligands. Additional examples of TRAIL polypeptides are those lacking not only the cytoplasmic domain and transmembrane region, but also all or part of the spacer region.

Due to the degeneracy of the genetic code, two DNA sequences may
5   differ, yet encode the same amino acid sequence. The present invention thus provides isolated DNA sequences encoding biologically active TRAIL, selected from DNA comprising the coding region of a native human or mammalian TRAIL cDNA, or fragments thereof, and DNA which is degenerate as a result of the genetic code to the native TRAIL DNA sequence.

10   A "variant" of TRAIL is a polypeptide that is not completely identical to native TRAIL. Such a variant TRAIL can be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or more amino acid. The amino acid sequence of the protein is modified, for example by substitution, to create a polypeptide having substantially the same or improved qualities as
15   compared to the native polypeptide. The substitution may be a conserved substitution. A "conserved substitution" is a substitution of an amino acid with another amino acid having a similar side chain. A conserved substitution would be a substitution with an amino acid that makes the smallest change possible in the charge of the amino acid or size of the side chain of the amino acid
20   (alternatively, in the size, charge or kind of chemical group within the side chain) such that the overall peptide retains its spacial conformation but has altered biological activity. For example, common conserved changes might be Asp to Glu, Asn or Gln; His to Lys, Arg or Phe; Asn to Gln, Asp or Glu and Ser to Cys, Thr or Gly. Alanine is commonly used to substitute for other amino acids. The
25   20 essential amino acids can be grouped as follows: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine having nonpolar side chains; glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine having uncharged polar side chains; aspartate and glutamate having acidic side chains; and lysine, arginine, and histidine having basic side chains.
30   L. Stryer, Biochemistry (2d ed.) p. 14-15; Lehninger, Biochemistry, p. 73-75.

The amino acid changes are achieved by changing the codons of the corresponding nucleic acid sequence. It is known that such polypeptides can be obtained based on substituting certain amino acids for other amino acids in the

13

polypeptide structure in order to modify or improve biologic activity, such as antigenic or immunogenic activity. For example, through substitution of alternative amino acids, small conformational changes may be conferred upon a polypeptide which result in increased activity. Alternatively, amino acid

5   substitutions in certain polypeptides may be used to provide residues which may then be linked to other molecules to provide peptide-molecule conjugates which retain sufficient biologic properties of

The variant TRAIL comprises at least the smallest region of TRAIL ligand or variant capable of inducing apoptosis through TRAIL receptors. The

10   degree of homology (percent identity) between a native and a variant sequence may be determined, for example, by comparing the two sequences using computer programs commonly employed for this purpose. One suitable program is the GAP computer program described by Devereux *et al.* (*Nucl. Acids Res.* 12:387, 1984), which is available from the University of Wisconsin Genetics

15   Computer Group.

The amino acid sequence of the variant TRAIL polypeptide corresponds essentially to the native TRAIL amino acid sequence. As used herein "corresponds essentially to" refers to a polypeptide sequence that will elicit a biological response substantially the same as the response generated by native

20   TRAIL. Such a response may be at least 60% of the level generated by native TRAIL, and may even be at least 80% of the level generated by native TRAIL. A variant of the invention may include amino acid residues not present in the corresponding native TRAIL or deletions relative to the corresponding native TRAIL.

25   Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequences. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the

30   transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However,

14

enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

5   Further, fusion proteins can be generated comprising operably linking multiple copies of the nucleic acid encoding TRAIL or heterologous DNA encoding one or more different proteins into the expression vector. These multiple nucleic acids may be separated by linkers. The fusion proteins may be produced using conventional recombinant DNA technology.

10   Expression vectors that may be used in the present invention are any vehicles capable of delivering the TRAIL gene, such as adenovirus, adeno-associated virus, herpesvirus, lentivirus, retroviruses, vaccinia, or naked DNA. In particular, the expression vector is a non-replicative adenovirus vector. The nucleic acid encoding TRAIL is operably linked to a promoter. The expression

15   vector contains an expression cassette, which is a nucleic acid segment comprising at least a first gene that one desires to have expressed and the necessary regulatory elements for expressing the gene in the target cell. Preferred regulatory elements for use with the invention include promoters, enhancers and terminators.

20   Most endogenous genes have regions of DNA that are known as promoters, which regulate gene expression. Promoter regions are typically found in the flanking DNA upstream from the coding sequence in both prokaryotic and eukaryotic cells. A promoter sequence provides for regulation of transcription of the downstream gene sequence and typically includes from

25   about 50 to about 2,000 nucleotide base pairs. Promoter sequences also contain regulatory sequences such as enhancer sequences that can influence the level of gene expression. Some isolated promoter sequences can provide for gene expression of heterologous DNAs, that is a DNA different from the native or homologous DNA.

30   Promoter sequences are also known to be strong or weak, or inducible. A strong promoter provides for a high level of gene expression, whereas a weak promoter provides for a very low level of gene expression. An inducible promoter is a promoter that provides for the turning on and off of gene

15

expression in response to an exogenously added agent, or to an environmental or developmental stimulus. Promoters can also provide for tissue specific or developmental regulation.

5   The expression cassette of the invention is operably linked to a promoter, which provides for expression of a linked DNA sequence. The DNA sequence is operably linked to the promoter when it is located downstream from the promoter, to form an expression cassette. An isolated promoter sequence that is a strong promoter for heterologous DNAs is advantageous because it provides for a sufficient level of gene expression. Preferred promoters will generally

10   include, but are not limited to, a strong mammalian promoter such as the cytomegalovirus promoter, the RSV promoter or any tissue-specific promoter.

The carrier for the TRAIL may be a fluid-based carrier, such as a saline solution, a slurry, such as a gelatin-based carrier, a matrix, collagens or polymers useful to enhance gene transfer or gene expression. For example, the carrier may

15   be Gelfoam®. The carrier may comprise additional compounds that can stimulate or enhance the immune system, such as a cytokine. Alternatively, the carrier may comprise one or more chemotherapeutic agents, radiotherapeutic agents, or immune potentiating genes or proteins. Such therapeutics effective against cancer are well known in the art.

20   According to the invention, cancer cells are treated in vivo by administration to a mammal afflicted with cancer of an effective amount of the vector containing the TRAIL gene. As used herein, an "effective amount" is that amount that results in an inhibition of growth of the target cancer cells. As described herein, a suitable dose is the vector level capable of inducing a

25   biologically relevant effect.

It will be appreciated that the amount of the compound, derivative thereof, required for use in treatment will vary not only with the particular solution selected but also with the nature of the condition being treated, and the age and condition of the patient. The amount will be ultimately at the discretion

30   of the attendant physician or clinician.

The composition of the present invention can be administered in conjunction with known anti-tumor chemotherapies and/or with known radiation therapies, and/or with known immune potentiating therapies.

The therapeutics described herein are believed to be effective in the treatment of solid mammalian tumors. These solid tumors include lung tumors, melanoma, mesothelioma, mediastinum tumors, esophagal tumors, stomach tumors, pancreal tumors, renal tumors, liver tumors, hepatobiliary system

5   tumors, small intestine tumors, colon tumors, rectum tumors, anal tumors, kidney tumors, ureter tumors, bladder tumors, prostate tumors, urethral tumors, testicular tumors, gynecological organ tumors, ovarian tumors, breast tumors, endocrine system tumors, or central nervous system tumors.

In the present invention, the entire coding sequence of human TRAIL

10   was cloned into the XhoI and NotI sties of pAd5CMVK-NpA (Fig. 1A). The resultant plasmid and adenovirus backbone sequences restricted of E1 were transfected into human embryonic kidney (HEK) 293 cells, and plaques were isolated and amplified for analysis of TRAIL expression.

Expression of the TRAIL protein results in its interaction with a death-

15   inducing TRAIL-receptor, whereby the cell is induced to die by apoptosis. The TRAIL/TRAIL receptor interaction takes place in the same cell or between adjacent cells. Only the TRAIL-sensitive tumor cells die in this procedure, whereas the surrounding normal tissue is not harmed. Addition of Brefeldin A, a fungal metabolite that specifically blocks protein transport from the endoplasmic

20   reticulum to the Golgi apparatus (and ultimately the cell surface), to the target cells inhibited TRAIL surface expression and subsequent apoptotic death.

The localized production of a membrane-bound form of TRAIL, instead of a soluble form, results in a high "local" concentration of TRAIL that is able to significantly influence tumor cell growth before elimination. This is the first use

25   of TRAIL in a gene transfer/gene therapy setting, which presents a variety of new possibilities for using TRAIL (the gene and/or the protein) as an antitumor agent.

The following examples are intended to illustrate but not limit the invention.

30

17

EXAMPLES

Example 1: Production of TRAIL-encoding adenovirus

The cDNA encoding human TRAIL (hTRAIL) was inserted into the E1
region of a replication deficient adenovirus type 5 construct under the control of
5   the CMV immediate early promoter (Figure 1A) to form an Ad-TRAIL vector.
The cDNA for hTRAIL was obtained from Dr. Hideo Yagita (Juntendo
University, Tokyo Japan, Ref. 25). A replication-deficient adenovirus encoding
the hTRAIL gene (Ad5-TRAIL) expressed from the cytomegalovirus (CMV)
promotor was generated using standard methods by the University of Iowa Gene
10   Transfer Vector Core (Iowa City, IA) (26). Briefly, the entire coding sequence
of human TRAIL was cloned into the XhoI and NotI sites of pAd5CMVK-NpA.
The resultant plasmid and adenovirus backbone sequences (adenovirus type 5;
Ref. 27) that had the E1 (E1A and E1B) genes deleted were transfected into
human embryonic kidney (HEK) 293 cells, and viral particles were isolated and
15   amplified for analysis of TRAIL expression. Recombinant adenoviruses
encoding nuclear-targeted bacterial β-galactosidase (Ad5-βgal) or green
fluorescent protein (Ad5-GFP) were used as virus controls. Recombinant
adenoviruses were screened for replication competent virus by A549 plaque
assay, and virus titer was determined by plaque assay on 293 cells. Purified
20   viruses were stored in PBS with 3% sucrose and kept at -80°C until use.

The Ad-TRAIL plasmid was transfected into HEK 293 cells to propagate
the virus. Cells were cultured in complete medium, and permitted to adhere for
at least 6 hoursbefore adding adenovirus. Prior to infection, cells were washed
with PBS, and then the vectors were added at the indicated number of plaque
25   forming units (pfu)/cell in culture medium supplemented as described above but
with only 2% FBS. After 4 hours, cells were washed with PBS and incubated in
complete medium for the remainder of the assay.

Ad5-TRAIL-infected 293 or uninfected 293 cells were lysed, and the
cellular proteins were separated by nonreducing SDS-PAGE to assay for TRAIL
30   expression by Western blotting. Cells were lysed in PBS containing 1% Nonidet
P-40, 0.35 mg/ml PMSF, 9.5 μg/ml Leupeptin, and 13.7 μg/ml Pepstatin A. The
lysed cells were centrifuged at 14,000 X g to remove cellular debris, and protein
concentrations of the lysates were determined by the colorimetric bicinchoninic

acid analysis (Pierce Chemical Company, Rockford, IL). Equal amounts of protein were separated by SDS-PAGE, transferred to nitrocellulose membrane (Novex, San Diego, CA), and blocked with 5% nonfat dry milk in PBS-Tween-20 (0.05% v/v) overnight. The membrane was incubated with the anti-caspase-8,

5   -PARP, or -hTRAIL mAb (diluted according to manufacturer's instructions) for 1 hours. After washing, the membrane was incubated with an anti-mouse or anti-rabbit-HRPO antibody (diluted 1:1000, Amersham, Arlington Heights, IL) for 1 hours. Antibodies against caspase-8 (provided by Dr. Marcus Peter, University of Chicago), poly (ADP-ribose) polymerase (PARP; Pharmingen, San

10   Diego, CA), and hTRAIL (PeproTech, Rocky Hill, NJ) were used for Western blotting according to manufacturer's instruction. Following several washes, the blots were developed by chemiluminescence according to the manufacturer's protocol (Renaissance chemiluminescence reagent, DuPont NEN, Boston, MA).

       Amino acid sequence analysis of the TRAIL cDNA predicts a weight of

15   32.5 kD for TRAIL monomers (9,10). As demonstrated in Figure 1B, prominent bands migrating at 32-35 kD and 55-58 kD are clearly evident, which correspond to TRAIL monomers and dimers, respectively. Higher order multimers may be present, but were difficult to clearly resolve. In contrast, no corresponding bands were present in the uninfected 293 cell lysate. Thus, these results demonstrate

20   that the adenoviral-mediated gene transfer of hTRAIL results in transgene expression in human cells.

       Example 2: Human tumor cells are susceptible to adenovirus infection

       One of the advantages of using an adenoviral vector lies in the ability to

25   infect epithelial cell populations. Group C adenovirus, such as Ad5, requires the interaction between the viral fiber capsid protein to the coxsackievirus and adenovirus receptor, or CAR, and the viral penton base binding to certain integrins (e.g. $\alpha_v\beta_3$ and $\alpha_v\beta_5$) for entry into the cell by receptor-mediated endocytosis (31-33). Therefore, a panel of human tumor cell lines (MDA 231,

30   mammary adenocarcinoma; PC-3, prostate carcinoma; RT-4, bladder papilloma; WM 164, melanoma; and WM 793, melanoma) were tested to verify that they would be receptive to adenoviral infection prior to examining the effects of Ad5-TRAIL infection.

The human prostate carcinoma cell line (PC-3) was obtained from Dr.
Michael Cohen (University of Iowa, Iowa City, IA). The human melanoma cell
lines (WM 164 and WM 793) were obtained from Dr. Meenhard Herlyn (Wistar
Institute, Philadelphia, PA). The human mammary adenocarcinoma cell line

5   (MDA 231) was obtained from Dr. David Lynch (Immunex Corporation, Seattle,
WA). The human bladder cancer cell line (RT-4) was obtained from Dr. Scott
Crist (University of Iowa, Iowa City, IA). PC-3, RT-4, WM 164, and WM 793
were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum, penicillin, streptomycin, sodium pyruvate, non-

10 essential amino acids, and HEPES (hereafter referred to as complete DMEM).
MDA 231 was cultured in RPMI 1640 supplemented with 10% fetal bovine
serum, penicillin, streptomycin, sodium pyruvate, non-essential amino acids, and
HEPES (hereafter referred to as complete RPMI). Normal human prostate
epithelial cells were obtained from Clonetics Corporation (San Diego, CA) and

15 cultured as directed.

The tumor cells were infected with either an adenovirus carrying the
enhanced green fluorescent protein gene (Ad5-GFP) or the β-galactosidase gene
(Ad5-βgal) for 4 hours, and then analyzed 20 hours later to determine adenoviral
infection efficiency and transferred gene expression. Cells infected with Ad5-

20 GFP were analyzed by flow cytometry on a FACScan (Becton Dickinson, San
Jose, CA) at various time points after infection to determine infection efficiency.
Cells infected with Ad5-βgal were assayed for β-galactosidase activity with the
Galacto-Light Plus chemiluminescent reporter gene assay system (Tropix,
Bedford, MA) to determine the level of transferred gene expression.

25 When infected with 1000 pfu/cell Ad5-GFP all of the tumor cell lines
demonstrated a high percentage of infectivity, ranging from 84.7-99.1% as
measured by flow cytometry (Figure 2A). Surface expression of TRAIL was
determined by measuring the binding of the anti-hTRAIL mAb M181 (mouse
IgG1; Immunex). Briefly, cells were incubated with 10 µg/ml M181 or MOPC-

30 21 (nonspecific mouse IgG1 isotype control, Sigma) in 3% BSA in PBS (PBSA)
for 30 minutes on ice. Following 3 washes with PBS, cells were incubated with
a PE-conjugated, Fc-specific goat anti-mouse F(ab')₂ (Jackson ImmunoResearch

Laboratories, West Grove, PA) for 30 minutes on ice. Finally, after 3 washes in PBS, the cells were analyzed on a FACscan (Becton Dickinson).

In addition, normal prostate epithelial cells (PrEC) were also found to be highly susceptible to Ad5-GFP infection (95.3%). Infection with Ad5-βgal
5   revealed that all of the cell types produced protein from the transferred gene in a pfu/cell dependent manner; however, there were greater differences in β-galactosidase activity between the different cell types than seen when examining GFP production (Fig. 2B). Thus, these results indicate that adenoviral-mediated transfer of the β-galactosidase and GFP reporter genes into the cells of interest
10   resulted in efficient gene transcription and translation into protein, suggesting that infection with Ad5-TRAIL should produce TRAIL protein in a similar percentage of cells.

Example 3: Production of TRAIL following Ad5-TRAIL infection leads to
15   tumor cell death

With the demonstration that the human tumor cell line panel was adequately infected with adenovirus, subsequent experiments were performed to examine the consequences of Ad5-TRAIL infection. Tumor cell sensitivity to Ad5-βgal, Ad5-GFP, or Ad5-TRAIL was assayed using the following procedure.
20   Cells were added to 96-well plates (2 X 10^4 cells/well) in complete medium, and then allowed to adhere for at least 6 hours before infection with the various adenoviral vectors as described above. As a positive control, recombinant soluble hTRAIL was added to the target cells at the indicated concentrations. In some experiments, z-VAD-fmk (20 μM), TRAIL-R2:Fc (20 μg/ml, Immunex),
25   Fas:Fc (20 μg/ml, Pharmingen) or Brefeldin A (5 μg/ml) was added to the medium during and after infection for the remainder of the assay. The tripeptide caspase inhibitor, z-VAD-fmk was obtained from Enzyme Systems Products (Livermore, CA). A stock solution of the inhibitor was prepared in DMSO and stored at 4°C. Brefeldin A was purchased from Epicentre Technologies
30   (Madison, WI), with a stock solution prepared in 100% EtOH and stored at -20°C. Cell death was determined after 20 hours by crystal violet staining as described (28). Results are presented as percent cell death: [1 - (O.D. cells treated per O.D. cells not treated)] X 100. For analysis of apoptosis, tumor cell

targets were incubated as described above and apoptotic cell death was measured by flow cytometry using FITC-conjugated annexin V (R&D Systems, Minneapolis, MN) and propidium iodide (Sigma, St. Louis, MO) as described (29,30).

5   The tumor cells were infected with either Ad5-βgal or Ad5-TRAIL for 4 hours, and then cultured for an additional 20 hours before determining the amount of cell death. As indicated in Figure 3A, minimal cell death of PC-3 cells was observed upon infection with Ad5-βgal. In contrast, a significant increase in cell death was seen with Ad5-TRAIL infection. Moreover, the level

10 of cell death induced by Ad5-TRAIL infection was comparable to that of soluble TRAIL-induced death. This cytotoxic activity was seen with other TRAIL-sensitive tumor cell targets, but not with the TRAIL-resistant melanoma cell line WM 164 or normal prostate epithelial cells (PrEC) (Table I).

15

Table I. Tumoricidal activity of adenovirus vectors versus TRAIL.			
Target cell	Ad5-βgal[1]	Ad5-TRAIL[1]	TRAIL[2]
MDA 231 (breast)	2.4 ± 1.4	44.7 ± 5.6	89.9 ± 0.9
PC-3 (prostate)	1.4 ± 1.8	85.5 ± 5.2	90.1 ± 8.7
RT4 (bladder)	1.3 ± 1.0	82.4 ± 6.1	89.4 ± 5.0
WM 164 (melanoma)	3.8 ± 2.1	1.2 ± 0.8	5.2 ± 2.7
WM 793 (melanoma)	2.5 ± 2.8	56.7 ± 9.7	86.6 ± 7.6
Normal prostate epithelium	13.1 ± 4.1	10.0 ± 2.6	14.3 ± 1.9

[1] Mean percent specific lysis (± S.D.) at 1000 pfu/cell.
[2] Mean percent specific lysis (± S.D.) with 1 μg/ml soluble TRAIL.

35   Analysis of TRAIL protein production by Western blot revealed detectable levels in PC-3 cell lysates by 1 hour post-infection, with levels increasing over the entire time course (Fig. 3B). In contrast, lysates from uninfected PC-3 cells or PC-3 cells examined 20 hours after Ad5-βgal infection had no detectable

TRAIL protein present. Thus, these results demonstrate that tumor cells infected with Ad5-TRAIL produce TRAIL protein that, presumably, leads to their death.

EXAMPLE 4: Ad5-TRAIL infection induces apoptosis in tumor cell targets

5   Although crystal violet staining of the tumor cells infected with the adenoviral vectors or treated with recombinant TRAIL as presented in Fig. 3 indicates the amount of cell death, it does not discriminate between apoptotic and necrotic cell death. Previous reports have demonstrated that TRAIL-induced cell death occurs through an apoptotic mechanism characterized by the activation

10   of a cascade of intracellular proteases, or caspases, and the cleavage of numerous intracellular proteins (9,10,14, 34-36). To confirm that the tumor cell death following Ad5-TRAIL infection was mediated through an apoptotic mechanism, caspase activation and cellular protein cleavage were examined. Thus, PC-3 cells were infected with Ad5-TRAIL for 4 hours, cell lysates were prepared at

15   various times after infection, and the cellular proteins were separated by SDS-PAGE for Western blot analysis of caspase-8 activation and poly (ADP-ribose) polymerase (PARP) cleavage. Activation of caspase-8 occurred within 2 hours after infection, while PARP cleavage took place by 4 hours after infection (Fig. 4A). By 20 hours after infection, the levels of the active p18 subunit of caspase-

20   8 and 85-kDa fragment of PARP had dropped below the level of detection, due to extensive apoptotic destruction. To further demonstrate the importance of caspase activation in the death of Ad5-TRAIL-infected cells, the caspase inhibitor z-VAD-fmk (carbobenzyloxy-Val-Ala-Asp (OMe) fluoromethyl ketone) was added to the culture medium throughout the assay. z-VAD-fmk

25   completely inhibited PC-3 cell death, whereas equal concentrations of the peptide vehicle (DMSO) did not (Fig. 4B).

A second critical event that takes place during apoptosis is the alteration in plasma membrane composition that appears to serve as a signal for phagocytes to recognize and engulf the apoptotic cells before membrane integrity is

30   compromised. It has been suggested that phosphatidylserine, a phospholipid component of the inner leaflet of the cell membrane that appears in the outer leaflet during apoptosis, serves as the marker for phagocytosis (37,38). Annexin V has been shown to preferentially bind to phosphatidylserine (39,40), and can

be used to detect the expression of phosphatidylserine on apoptotic cells (29,30).
Thus, PC-3 cells infected with Ad5-βgal or Ad5-TRAIL were analyzed for
annexin V binding. Upon staining the PC-3 cells 6 hours after infection or
incubation with soluble hTRAIL (100 ng/ml), only those cells infected with
5   Ad5-TRAIL or incubated with soluble hTRAIL were positive for FITC-annexin
V binding (Fig. 4C), providing further evidence that the death of the Ad5-
TRAIL-infected tumor cells was through an apoptotic mechanism.
Morphological changes, such as membrane blebbing and the release of apoptotic
bodies, were also observed in cells infected with Ad5-TRAIL using light
10   microscopy.

**EXAMPLE 5: Ad5-TRAIL-induced death can be inhibited with Brefeldin
A, but not TRAIL receptor:Fc**

The results obtained thus far demonstrated that Ad5-TRAIL infection leads
15   to TRAIL protein production and the subsequent induction of apoptotic cell
death. However, it was important to also demonstrate the cell death to be a
TRAIL-dependent phenomenon with the expression of TRAIL on the surface of
the infected cells. Thus, the TRAIL-resistant (both soluble TRAIL (recombinant
soluble hTRAIL was purchased from PeproTech and used at the indicated
20   concentrations) and Ad5-TRAIL) human melanoma WM164 was infected with
Ad5-βgal or Ad5-TRAIL as in previous experiments, and then analyzed for
TRAIL expression by flow cytometry after 8 hours. TRAIL-resistant WM 164
cells were used because the cell death that occurred in the TRAIL-sensitive PC-3
cells following Ad5-TRAIL infection made them difficult to analyze accurately
25   as non-specific staining increased as the cells became apoptotic. Whereas no
TRAIL was detectable on uninfected or Ad5-βgal-infected WM 164 cells, those
cells infected with Ad5-TRAIL did express TRAIL on the cell surface (Fig. 5A).
Interestingly, treatment of the Ad5-TRAIL-infected WM 164 cells with
Brefeldin A (BFA) resulted in the inhibition of TRAIL expression at the cell
30   surface. BFA blocks the anterograde migration of proteins through the Golgi
complex, and thus prevents their expression on the cell surface. The BFA
treatment did not, however, inhibit the production of TRAIL protein as both

treated and untreated Ad5-TRAIL-infected WM 164 cell lysates contained TRAIL protein as determined by Western blotting (Fig. 5B).

Since TRAIL must bind to TRAIL-R1 or -R2 (the death domain, death-inducing TRAIL receptors) to initiate the apoptotic process, it was predicted that
5   disruption of this interaction would protect the TRAIL-sensitive tumor cells from Ad5-TRAIL-induced death. To test this, PC-3 cells were infected with Ad5-TRAIL and then cultured for 20 hours in medium alone, or medium containing the recombinant soluble receptors for TRAIL (TRAIL-R2:Fc, Ref. 14) or Fas (Fas:Fc). Surprisingly, TRAIL-R2:Fc did not inhibit cell death in the
10   Ad5-TRAIL-infected PC-3 cells (Fig. 6A) at concentrations that completely inhibited cell death induced by soluble TRAIL. It was reasoned that since the PC-3 cells are adherent, nonpolarized cells TRAIL could be expressed on surfaces that were inaccessible to TRAIL-R2:Fc, but still able to engage the TRAIL-R1 or -R2 expressed there. Seeing that BFA could inhibit the expression
15   of TRAIL (Fig. 5A), the same experiment was tried but in the presence of BFA or its vehicle EtOH. In this setting, the addition of BFA was able to block the cell death resulting from Ad5-TRAIL infection, whereas EtOH did not (Fig. 6B). This inhibition by BFA did not interfere with the signaling mechanism of TRAIL-R1/R2 as BFA-treated PC-3 cells were as sensitive to soluble TRAIL-
20   induced death as those cultured without BFA (data not shown).

Further support for TRAIL-mediated killing following Ad5-TRAIL infection was obtained by using Ad5-TRAIL-infected PrEC or WM 164 cells to induce apoptosis in PC-3 target cells. PrEC or WM 164 were infected with 1000 pfu/cell Ad5-TRAIL for 4 hours, incubated in complete medium for 12 hours,
25   washed, and resuspended in complete medium. PC-3 tumor cells were labeled with 100 μCi of ^{51}Cr for 1 hour at 37°C, washed three times, and resuspended in complete medium. To determine TRAIL-induced death, ^{51}Cr-labeled tumor cells (10^4/well) were incubated with varying numbers of Ad5-TRAIL/WM 164 effector cells for 8 hours. As a positive control, soluble TRAIL was added to the
30   target cells at the indicated concentrations. In some cultures, TRAIL-R2:Fc or Fas:Fc (20 μg/ml) were added to the Ad5-TRAIL/WM 164 effector cells 15 minutes prior to adding tumor cell targets. Assays were performed in round-bottom 96-well plates and the percent specific lysis was calculated as: 100 X

25

(experimental c.p.m. - spontaneous c.p.m.)/(total c.p.m. - spontaneous c.p.m.). Spontaneous and total release were determined in the presence of either medium alone or 1% NP-40, respectively. The presence of TRAIL-R2:Fc or Fas:Fc during the assay had no effect on the level of spontaneous release of ^{51}Cr by the

5   target cells.

Whereas uninfected PrEC or WM 164 demonstrated no cytolytic activity against the PC-3 target cells, the Ad5-TRAIL-infected cells displayed comparable activity to soluble TRAIL (Figure 6C). This activity was TRAIL-specific, as inclusion of soluble TRAIL-R2:Fc, but not Fas:Fc, to the Ad5-

10   TRAIL-infected WM 164 cells blocked target cell lysis (Figure 6D). Similar results were also obtained with PrEC (data not shown). Collectively, the results presented in Figures 5 and 6 demonstrate that the apoptotic death following Ad5-TRAIL infection results from TRAIL expression on the cell surface where it binds to either TRAIL-R1 or -R2.

15

Example 6: Analysis of adenoviral transgene expression following intratumoral injection

CB.17 SCID mice were pretreated 24 hours before tumor challenge with a single injection (100 µl, intraperitoneally) of purified anti-asialo GM-1 antibody

20   (Wako Chemicals, Richmond, VA). Mice were challenged with either the human mammary adenocarcinoma cell line (MDA 231; 10^6 cells/site) or bladder cancer cell line (RT-4; 5×10^6 cells/site) by subcutaneous injection. Tumors were allowed to grow until they were at least 25 mm^2 before the adenoviral vectors recombinant for the reporter genes luciferase (Ad2-luc) or β-

25   galactosidase (Ad5-βgal) were injected at a concentration of 3×10^7 plaque forming units (pfu)/ml in PBS (phosphate buffered saline) alone or with Gelfoam® (30 mg/ml; Pharmacia and Upjohn, Kalamazoo, MI). Gelfoam® is an absorbable gelatin sponge prepared from purified pork skin gelatin and is commonly used as a hemostatic agent. Injection volume was 100 ml, making the

30   final concentration 3×10^6 pfu/ injection. Tumors were harvested for reporter gene assays at various times after injection.

The luciferase assay or β-galactosidase was performed using a commercial luciferase (Promega Corp., Madison, WI) or β-galactosidase (Tropix, Bedford,

26

MA) assay kit after homogenizing each tumor. Samples were analyzed on a
Monolight 2010 Luminometer (Analytical Luminescence Laboratory, Ann
Arbor, MI).

5   **Example 7: Inhibition of tumor growth with Ad5-TRAIL**

CB.17 SCID mice were pretreated 24 hours before tumor challenge with a
single injection (100 µl, intraperitoneally) of purified anti-asialo GM-1 antibody.
Mice were challenged with the human bladder cancer cell line RT-4 (5×10^6
cells/site) by subcutaneous injection. Mice were then treated with either PBS
10   alone, Ad5-TRAIL in PBS, Ad5-TRAIL with matrix, Ad5-βgal in PBS, or Ad5-
βgal with matrix (10^9 pfu/injection) 24 hours later. Tumor size was measured
weekly.

The Ad5-TRAIL treatment is also useful for the treatment of established
tumors. Tumors are implanted and then the Ad5-TRAIL treatment is begun days
15   later (Day 0, implant; Day 1, 5, 7, 10, 14, 21 inject Ad5-TRAIL). Tumor size is
measured before and after treatment.

The Ad5-TRAIL treatment can be administered as multiple Ad5-TRAIL
injections as opposed to a single injection. Experimental groups are set up as
above, but with groups receiving multiple Ad5-TRAIL injections at regular
20   intervals.

All publications, patents and patent documents are incorporated by
reference herein, as though individually incorporated by reference. The
invention has been described with reference to various specific and preferred
25   embodiments and techniques. However, it should be understood that many
variations and modifications may be made while remaining within the scope of
the invention.

27

REFERENCES

1. Armitage, R. J. 1994. Tumor necrosis factor receptor superfamily members and their ligands. *Curr. Opin. Immunol. 6:407.*

2. Cosman, D. 1994. A family of ligands for the TNF receptor superfamily. *Stem Cells 12:440.*

3. Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M. E. Peter. 1998. Apoptosis signaling by death receptors. *Eur. J. Biochem. 254:439.*

4. Cerami, A., and B. Beutler. 1988. The role of cachectin/TNF in endotoxic shock and cachexia. *Immunol. Today 9:28.*

5. Zheng, L. X., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumor necrosis factor. *Nature 377:348.*

6. Alderson, M. R., T. W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. A. Schooley, R. G. Goodwin, C. A. Smith, F. Ramsdell, and D. H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. *J. Exp. Med. 181:71.*

7. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science 270:1189.*

8. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. *Science 274:1363.*

9. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C.-P. Huang, J. K. Nicholl, G. R. Sutherland, T. Davis Smith, C. Rauch, C. A. Smith, and R. G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity 3:673.*

10. Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J. Biol. Chem. 271:12687.*

11. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. *Science 276:111.*

12. Pan, G., J. Ni, Y.-F. Wei, G.-I. Yu, R. Gentz, and V. M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science 277:815.*

13. Sheridan, J. P., S. A. Marsters, P. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and A. Ashkenazi. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science 277:818.*

14. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin, and C. T. Rauch. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. *EMBO J. 16:5386.*

15. MacFarlane, M., M. Ahmad, S. M. Srinivasula, T. Fernandes-Alnemri, G. M. Cohen, and E. S. Alnemri. 1997. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J. Biol. Chem. 272:25417.*

16. Degli-Esposti, M. A., P. J. Smolak, H. Walczak, J. Waugh, C.-P. Huang, R. F. DuBose, R. G. Goodwin, and C. A. Smith. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. *J. Exp. Med. 186:1165.*

17. Degli-Esposti, M. A., W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin. 1997. The novel receptor TRAIL-R4 induces NFκB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity 7:813.*

18. Marsters, S. A., J. P. Sheridan, R. M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A. D. Goddard, P. Godowski, and A. Ashkenazi. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol. 7:1003.*

19. Pan, G., J. Ni, G. Yu, Y.-F. Wei, and V. M. Dixit. 1998. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. *FEBS Lett. 424:41.*

20. Walczak, H., R. E. Miller, B. Gliniak, K. Ariail, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin,

C. T. Rauch, J. C. L. Schuh, and D. H. Lynch. 1999. Tumoricidal activity of TRAIL *in vivo*. *Nat. Med. 5:157*.

21. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R. H. Schwall. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. *J. Clin. Invest. 104:155*.

22. Gliniak, B., and T. Le. 1999. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity *in vivo* is enhanced by the chemotherapeutic agent CPT-11. *Cancer Res. 59:6153*.

23. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. *J. Exp. Med. 187:1205*.

24. Ogasawara, J., F. R. Watanabe, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. *Nature 364:806*.

25. Kayagaki, N., N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, and H. Yagita. 1999. Involvement of TNF-related apoptosis-inducing ligand in human CD4[+] T cell-mediated cytotoxicity. *J. Immunol. 162:2639*.

26. Ooboshi, H., Y. Chu, C.D. Rios, F. M. Faraci, B. L. Davidson, and D. D. Heistad. 1997. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. *Am. J. Physiol. Heart Circ. Physiol. 273:H265*.

27. Jones, N., and T. Shenk. 1979. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. *Cell 17:683*.

28. Flick, D. A., and G. E. Gifford. 1994. Comparison of *in vitro* cell cytotoxic assays for tumor necrosis factor. *J. Immunol. Meth. 68:167*.

29. Koopman, G., C. P. M. Reutelingsperger, G. A. M. Kuijten, R. M. J. Keehnen, S. T. Pals, and M. H. J. van Oers. 1994. Annexin V for flow

30

cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood. 84:1415.*

30. Martin, S. J., C. P. M. Reutelingsperger, A. J. McGahon, J. A. Rader, R. C. A. A. van Schie, D. M. LaFace, and D. R. Green. 1995. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. *J. Exp. Med. 182:1545.* .

31. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ promote adenovirus internalization but not virus attachment. *Cell 23:309.*

32. Bergelson, J. M., J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong, M. S. Horwitz, R. L. Crowell, and R. W. Finberg. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. *Science 275:1320.*

33. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc. Natl. Acad. Sci. USA. 94:3352.*

34. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. *Immunity 7:821.*

35. Schneider, P., M. Thome, K. Burns, J. L. Bodmer, K. Hofmann, T. Kataoka, N. Holler, and J. Tschopp. 1997. TRAIL receptors 1(DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. *Immunity 7:831.*

36. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. *J. Immunol. 161:2833.*

37. Fadok, V. A., D. R. Voelker, P. A. Campbell, J. J. Cohen, D. L. Bratton, and P. M. Henson. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. *J. Immunol. 148:2207.*

38. Fadok, V. A., J. S. Savill, C. Haslett, D. L. Bratton, D. E. Doherty, P. A. Campbell, and P. M. Henson. 1992. Different populations of macrophages

31

use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. *J. Immunol. 149:4029.*

39. Thiagarajan, P., and J. F. Tait. 1990. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. *J. Biol. Chem. 265:17420.*

40. Raynal, P., and H. B. Pollard. 1994. Annexins: the problem of assessing the biological role for a gene family of multifinctional clacium and phospholipid-binding proteins. *Biochim. Biophys. Acta. 1197:63.*

41. Willimsky, G., and T. Blankenstein. 2000. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted by not nontransplanted tumors. *Cancer Res. 60:685.*

42. Lu, W., I. J. Fidler, and Z. Dong. 1999. Eradication of primary murine fibrosacromas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. *Cancer Res. 59:5202.*

43. Stewart, A. K., N. J. Lassam, I. C. Qquirt, D. J. Bailey, L. E. Rotstein, M. Krajden, S. Dessureault, S. Gallinger, D. Cappe, Y. Wan, C. L. Addison, R. C. Moen, J. Gauldie, and F. L. Craham. 1999. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial. *Gene Ther. 6:350.*

44. Hirschowitz, E. A., H. A. Naama, D. Evoy, M. D. Lieberman, J. Daly, and R. G. Crystal. 1999. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma. *Cancer Gene Ther. 6:491.*

45. Nasu, Y., C. H. Bangma, G. W. Hull, H. M. Lee, J. Hu, J. Wang, M. A. McCurdy, S. Shimura, G. Yang, T. L. Timme, and T. C. Thompson. 1999. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. *Gene Ther. 6:338.*

46. Mazzolini, G., C. Quin, X. Xie, Y. Sun, J. J. Lasarte, M. Drozdzik, and J. Prieto. 1999. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. *Cancer Gene Ther. 6:514.*

47. Atkinson, G., and S. J. Hall. 1999. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. *Urology 54:1098.*

48. Xie, Y., J. D. Gilbert, J. H. Kim, and S. O. Freytag. 1999. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. *Clin. Cancer Res. 5:4224.*

49. Arai, H., D. Gordon, E. G. Nabel, and G. J. Nabel. 1997. Gene transfer of Fas ligand induces tumor regression *in vivo. Proc. Natl. Acad. Sci. USA. 94:13862.*

50. Ambar, B. B., K. Frei, U. Malipiero, A. E. Morelli, M. G. Castro, R. P. Lowerstein, and A. Fontana. 1999. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. *Hum. Gene Ther. 10:1641.*

51. Hedlund, T. E., S. J. Meech, S. Srikanth, A. S. Kraft, G. J. Miller, J. B. Schaack, and R. C. Duke. 1999. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. *Cell Death Diff. 6:175.*

52. Griffith, T. S., and D. H. Lynch. 1998. TRAIL: a molecule with multiple receptors and control mechanisms. *Curr. Opin. Immunol. 10:559.*

53. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. *Nature 388:190.*

54. Leverkus, M., M. Neumann, T. Mengling, C. T. Rauch, E.-B. Brocker, P. H. Krammer, and H. Walczak. 2000. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. *Cancer Res. 60:553.*

55. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature 392:86.*

56. Albert, M. L., S. F. A. Pearce, L. M. Francisco, B. Sauter, P. Roy, R. L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose

apoptotic cells via $\alpha_v\beta_5$ and CD36, and cross-present antigens to cytotoxic T lymphocytes. *J. Exp. Med. 188:1359.*

57. Giovarelli, M., P. Musiani, G. Garotta, R. Ebner, E. Di Carlo, Y. Kim, P. Cappello, L. Rigamonti, P. Bernabei, F. Novelli, A. Modesti, A. Coletti, A. K. Ferriem, P.-L. Lollini, S. Ruben, T. Salcedo, and G. Forni. 1999. A "stealth effect": Adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. *J. Immunol. 163:4886.*

58. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. *J. Exp. Med. 184:1075.*

59. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, D. Roche, J. Kelly, J. K. Collins, and F. Shanahan. 1998. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. *J. Pathol. 186:240.*

60. Bennett, M. W., J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan. 1998. The Fas counterattack *in vivo*: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. *J. Immunol. 160: 5669.*

61. Landis, S. H., T. Murray, S. Bolden, and P. A. Wingo. 1999. Cancer statistics, 1999. *CA Cancer J. Clin. 49:8.*

WHAT IS CLAIMED IS:

1.   A method for inhibiting tumor cell growth in a mammal afflicted with a tumor comprising administering a vector comprising a DNA expression cassette

5   comprising a promoter and a DNA sequence encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), wherein the expression of TRAIL results in tumor inhibition.

2.   The method of claim 1, wherein the vector is a non-replicative viral

10   vector.

3.   The method of claim 1, wherein the vector is adenovirus, adeno-associated virus, herpesvirus, lentivirus, retrovirus, vaccinia virus, or naked DNA.

15

4.   The method of claim 2, wherein the vector is an adenoviral vector.

5.   The method of claim 1, wherein the TRAIL is human TRAIL.

20   6.   The method of claim 1, wherein the promoter is a cytomegalovirus promoter, a Rous Sarcoma Virus promoter, or a tissue-specific promoter.

7.   The method of claim 6, wherein the promoter is a cytomegalovirus promoter.

25

8.   The method of claim 1, wherein the expression cassette further comprises a regulatory element.

9.   The method of claim 8, wherein the regulatory element is an enhancer,

30   regulator of TRAIL expression, or regulator controlling viral replication.

10.   The method of claim 1, wherein the tumor is a solid tumor.

11.   The method of claim 10, wherein the tumor is cancerous.

12.   The method of claim 10, wherein the solid tumor is a lung tumor, a
melanoma, a mesothelioma, a mediastinum tumor, esophagal tumor, stomach
5   tumor, pancreal tumor, renal tumor, liver tumor, hepatobiliary system tumor,
small intestine tumor, colon tumor, rectum tumor, anal tumor, kidney tumor,
ureter tumor, bladder tumor, prostate tumor, urethral tumor, testicular tumor,
gynecological organ tumor, ovarian tumor, breast tumor, endocrine system
tumor, or central nervous system tumor.
10

13.   The method of claim 1, wherein the vector is administered by injection.

14.   The method of claim 1, wherein the vector is administered in
combination with a pharmaceutically acceptable carrier.
15

15.   The method of claim 14, wherein the pharmaceutically acceptable carrier
is a solution.

16.   The method of claim 14, wherein the pharmaceutically acceptable carrier
20   a slurry or matrix.

17.   The method of claim 14, wherein the pharmaceutically acceptable carrier
is in Gelfoam®.

25   18.   The method of claim 14, wherein the carrier further comprises an
immune enhancing agent.

19.   The method of claim 18, wherein the immune enhancing agent is a
cytokine.
30

20.   The method of claim 14, wherein the solution further comprises an agent
that enhances gene delivery or expression.

21.   The method of claim 1, wherein the mammal is a human.

22.   The method of claim 1, further comprising administering a
chemotherapeutic agent, radiotherapeutic agent, or an immune potentiating gene
5   or protein.

23.   A method for causing tumor regression in a mammal afflicted with a
tumor comprising administering to a TRAIL-sensitive cell a vector comprising
DNA encoding TRAIL, wherein the expression of TRAIL results in tumor
10   regression.

24.   A method of eliminating tumor cells from a mammal afflicted with a
tumor comprising administering to a TRAIL-sensitive cell a vector comprising
DNA encoding TRAIL, wherein the expression of TRAIL results in tumor
15   elimination.

A.

B.

FIG. 1

BEST AVAILABLE COPY

MDA 231

99.1%

RT-4

88.8%

PC-3

97.5%

WM 164

88.2%

PrEC

95.3%

WM 793

84.7%

FIG. 2A

SUBSTITUTE SHEET (RULE 26)   BEST AVAILABLE COPY

FIG. 2B

FIG. 3A

FIG. 3B

FIG. 4A

BEST AVAILABLE COPY

FIG. 4B

FIG. 4C

FIG. 5A

FIG. 5B

A.

B.

C.

D.

FIG. 6

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7   C12N15/12   A61K48/00   A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE, CANCERLIT, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SON K: "Cisplatin-based tumor necrosis factor-related apoptosis-inducing ligand (trail) gene therapy of human breast carcinoma resistant to drugs or hormone." BREAST CANCER RESEARCH AND TREATMENT., vol. 57, no. 1, 1999, page 54 XP001016214 22nd Annual San Antonio Breast Cancer Symposium; San Antonio, Texas, USA; December 8-11, 1999 ISSN: 0167-6806	1,5, 8-15, 20-24
Y	abstract 177	2-4,6,7, 16-19

-/-

[X]	Further documents are listed in the continuation of box C.		[X]	Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 August 2001	13/09/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Sitch, W

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 4

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
Y	ROTH ET AL: "Death ligands/death receptors, New weapons against malignant glioma" NEUROFORUM, vol. 5, no. 3, 1999, pages 87-92, XP001016223 page 88; table 2 page 89, paragraph 4 -page 90, paragraph 4 page 91, paragraph 2	2-4,6
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 March 1998 (1998-03-20) PUTZER B M ET AL: "Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer." Database accession no. PREV199800230442 XP002176067 abstract & HUMAN GENE THERAPY, vol. 9, no. 5, 20 March 1998 (1998-03-20), pages 707-718, ISSN: 1043-0342	7
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 March 2000 (2000-03-01) SIEMENS D ROBERT ET AL: "Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model." Database accession no. PREV200000152081 XP002176068 abstract & JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA)., vol. 92, no. 5, 1 March 2000 (2000-03-01), pages 403-412, ISSN: 0027-8874	16,17
Y	WO 97 25428 A (GENENTECH INC) 17 July 1997 (1997-07-17) page 1, line 6 - line 8 page 20, line 36 -page 22, line 19	18,19

-/—

BNSDOCID: <WO   0179495A1_I_>

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	CHINNAIYAN ARUL M ET AL: "Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 4, 15 February 2000 (2000-02-15), pages 1754-1759, XP002176061 Feb. 15, 2000 ISSN: 0027-8424 page 1754 abstract	22
A	ASHKENAZI AVI ET AL: "Safety and antitumor activity of recombinant soluble Apo2 ligand." JOURNAL OF CLINICAL INVESTIGATION, vol. 104, no. 2, July 1999 (1999-07), pages 155-162, XP002176062 ISSN: 0021-9738 cited in the application page 155 abstract	1
A	GLINIAK BRIAN ET AL: "Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11." CANCER RESEARCH, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6153-6158, XP002176063 ISSN: 0008-5472 cited in the application page 6153 abstract	1
A	WALCZAK HENNING ET AL: "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo." NATURE MEDICINE, vol. 5, no. 2, February 1999 (1999-02), pages 157-163, XP002176064 ISSN: 1078-8956 cited in the application page 157 abstract	1

-/--

RNSDOCID: <WO   0179405A1 I >

Inte   Application No

PCT/US 01/11831

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
P,X	GRIFFITH T S ET AL: "Adenoviral—mediated gene transfer of TRAIL induces tumor cell apoptosis." FASEB JOURNAL, vol. 14, no. 6, 20 April 2000 (2000-04-20), page A1003 XP002176065 Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society;Seattle, Washington, USA; May 12-16, 2000 ISSN: 0892-6638 abstract 53.23	1-5, 8-15,21, 23,24
P,X	GRIFFITH ET AL: "ADENOVIRAL-MEDIATED TRANSFER OF THE TNF-RELATED APOPTOSIS-INDUCING LIGAND/APO-2 LIGAND GENE INDUCES TUMOR CELL APOPTOSIS" JOURNAL OF IMMUNOLOGY, vol. 165, September 2000 (2000-09), pages 2886-2894, XP002176066 page 2886 abstract page 2887, paragraph 3 page 2888; figure 1	1-15,21, 23,24

International pplication No

PCT/US 01/11831

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9725428 A	17-07-1997	US 6030945 A	29-02-2000
		AU 729279 B	01-02-2001
		AU 1824897 A	01-08-1997
		CA 2241572 A	17-07-1997
		EP 0873407 A	28-10-1998